Optimal use of β-blockers in high-risk hypertension: A guide to dosing equivalence
Author(s): Janet B McGillJournal: Vascular Health and Risk Management ISSN 1176-6344
Volume: 2010; Issue: default; Start page: 363; Date: 2010;
Original page
ABSTRACT
Janet B McGillDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, USAAbstract: Hypertension is the number one diagnosis made by primary care physicians, placing them in a unique position to prescribe the antihypertensive agent best suited to the individual patient. In individuals with diabetes mellitus, blood pressure (BP) levels > 130/80 mmHg confer an even higher risk for cardiovascular and renal disease, and these patients will benefit from aggressive antihypertensive treatment using a combination of agents. βâblockers are playing an increasingly important role in the management of hypertension in high-risk patients. βâblockers are a heterogeneous class of agents, and this review presents the differences between βâblockers and provides evidence-based protocols to assist in understanding dose equivalence in the selection of an optimal regimen in patients with complex needs. The clinical benefits provided by βâblockers are only effective if patients adhere to medication treatment long term. βâblockers with proven efficacy, once-daily dosing, and lower side effect profiles may become instrumental in the treatment of hypertensive diabetic and nondiabetic patients.Keywords: antihypertensive, blood pressure, atenolol, carvedilol, labetalol, metoprolol, nebivolol
Add to my list
My list